Neurology

In instances when longer term treatment is required, continued use of IG should be based on objective measures of effectiveness established at the outset of treatment. These measures should be assessed no later than 6 months after initiation of treatment and at least annually thereafter. If clinical effectiveness has not been achieved, IG should be discontinued.

Acute disseminated encephalomyelitis (ADEM)

Recommended Indications in which IG can be used:
Order Number: N1-ADEM

Acute optic neuritis

Do Not Use

Adrenoleukodystrophy

Do Not Use

Alzheimer disease

Do Not Use

Autism

Do Not Use

Autoimmune encephalitis mediated by antibodies (AMAE) targeting cell-surface antigens

Recommended Indications in which IG can be used:
Order Number: N2-AMAE

Axonal Neuropathy associated with IgM paraproteinemia

Do Not Use

Chronic fatigue syndrome (myalgic encephalomyelitis)

Do Not Use

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Recommended Indications in which IG can be used:
Order Number: N3-CIDP

Critical illness polyneuropathy (CIP)

Do Not Use